* Bioventus Inc BVS.OQ BVS.O is expected to show a fall
in
quarterly revenue when it reports results on March 12 for the
period ending December 31 2023
* The Durham North Carolina-based company is expected to
report a
1.5% decrease in revenue to $123.958 million from $125.83
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Bioventus Inc is for
earnings
of 2 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$6.50, above its last closing price of $5.52.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.02 -0.02 0.05 Beat 350
Jun. 30 2023 0.01 0.00 0.14 Beat
Mar. 31 2023 -0.15 -0.15 -0.26 Missed -73.3
Dec. 31 2022 0.05 0.05 -0.06 Missed -226.3
Sep. 0.12 0.12 0.08 Missed -34.4
30 2022
Jun. 30 2022 0.15 0.16 0.10 Missed -35.9
Mar. 31 2022 0.05 0.05 0.04 Missed -16.7
Dec. 31 2021 0.17 0.18 0.26 Beat 46.5
This summary was machine generated March 8 at 13:18 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)